Liraglutide causes large and rapid epicardial fat reduction

Cited by (251)

Items 101–200 of 251

1. Increased Epicardial Adipose Tissue (EAT), Left Coronary Artery Plaque Morphology, and Valvular Atherosclerosis as Risks Factors for Sudden Cardiac Death from a Forensic Perspective
   Timur Hogea, Bogdan Andrei Suciu, Adrian Dumitru Ivănescu, Cosmin Carașcă, Laura Chinezu, Emil Marian Arbănași, Eliza Russu, Réka Kaller, Eliza Mihaela Arbănași, Adrian Vasile Mureșan et al. · 2023 · Diagnostics
2. Epicardial fat and ventricular arrhythmias
   Marta Załęska‐Kocięcka, Zuzanna Wojdyńska, Małgorzata Kalisz, Anna Litwiniuk, Michał Ma̧czewski, Przemysław Leszek, Aleksandra Paterek · 2023 · Heart Rhythm
3. Epicardial Fat Tissue: A Potential Marker for Coronary Microvascular Dysfunction
   Waiel A. Abusnina, Ilan Merdler, Matteo Cellamare, Kalyan R. Chitturi, Abhishek Chaturvedi, Irwin M. Feuerstein, Cheng Zhang, Sevket Tolga Ozturk, Teshome Deksissa, Vaishnavi Sawant et al. · 2025 · Journal of the American Heart Association
4. The Effects of Heme Oxygenase Upregulation on Obesity and the Metabolic Syndrome
   Stephen J. Peterson, Niel Dave, Janish Kothari · 2019 · Antioxidants and Redox Signaling
5. The potential of glucagon-like peptide-1 receptor agonists in heart failure
   Frederik Flindt Kreiner, G. Kees Hovingh, Bernt Johan von Scholten · 2022 · Frontiers in Physiology
6. Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction
   Zifeng Yang, Ruifeng Tian, Xiao‐Jing Zhang, Jingjing Cai, Zhi‐Gang She, Hongliang Li · 2023 · Frontiers in Cardiovascular Medicine
7. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
   Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, Alessandra Scatteia, Giandomenico Bisaccia, Salvatore De Rosa, Santo Dellegrottaglie, Chiara Bucciarelli‐Ducci, Daniele Torella, Isabella Leo · 2024 · Cardiovascular Diabetology
8. Epicardial fat in heart failure—Friend, foe, or bystander
   Aleksandra Paterek, Marta Załęska‐Kocięcka, Zuzanna Wojdyńska, Małgorzata Kalisz, Anna Litwiniuk, Przemysław Leszek, Michał Ma̧czewski · 2024 · Obesity Reviews
9. Recent update on biological activities and pharmacological actions of liraglutide
   Juhi Tiwari, Gaurav Gupta, Rajiv Dahiya, Kavita Pabreja, Rakesh Kumar Sharma, Anurag Mishra, Kamal Dua · 2017 · EXCLI journal
10. Epicardial fat inflammation response to COVID‐19 therapies
    Gianluca Iacobellis, Alexis Elias Malavazos, Sara Basilico, Silvia Tresoldi, Rocco Francesco Rinaldo, Carola Dubini, Gloria Capitanio, Francesca Serpi, Simone Schiaffino, O. Oliva et al. · 2021 · Obesity
11. Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease
    Nour‐Mounira Z. Bakkar, Ibrahim AlZaim, Ahmed Fawzy EL‐Yazbi · 2022 · Clinical Science
12. Cardiac Adiposity and Arrhythmias: The Role of Imaging
    Maria S. Bonou, Sophie I. Mavrogeni, Chris J. Kapelios, George Markousis‐Mavrogenis, Constantina Aggeli, Εvangelos Cholongitas, Athanase D. Protogerou, John D. Barbetseas · 2021 · Diagnostics
13. Epicardial Adipose Tissue: a Potential Therapeutic Target for Cardiovascular Diseases
    Wen-xi Fang, Saiyang Xie, W. Deng · 2023 · Journal of Cardiovascular Translational Research
14. Dysfunctional EAT thickness may promote maladaptive heart remodeling in CVD patients through the ST2-IL33 system, directly related to EPAC protein expression
    Elena Vianello, Elena Dozio, Francesco Bandera, Gerd Schmitz, Manuela Nebuloni, Erika Longhi, Lorenza Tacchini, Marco Guazzi, Massimiliano Marco Corsi Romanelli · 2019 · Scientific Reports
15. Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
    Francesc Villarroya, Marion Peyrou, Marta Giralt · 2025 · Current Obesity Reports
16. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry
    David García‐Vega, Sergio Cinza‐Sanjurjo, Sonia Eirás, José Ramón González‐Juanatey · 2024 · The American Journal of Medicine
17. Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo‐controlled trial
    Ida Kirstine Bull Rasmussen, Emilie H. Zobel, Rasmus Sejersten Ripa, Bernt Johan von Scholten, Viktor Rotbain Curovic, Jacob Kildevang Jensen, Andreas Kjær, Tine W. Hansen, Peter R Rossing · 2021 · Diabetes Obesity and Metabolism
18. Impact of obesity on atrial fibrillation ablation
    Valentina Mangiafico, Bunny Saberwal, Carlo Lavalle, Antony Raharja, Zuhair Ahmed, Νικόλαος Παπαγεωργίου, Syed Ahsan · 2020 · Archives of cardiovascular diseases
19. Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies
    Wenwen Zheng, Qianxian Qi, Jie Li, Chao‐Jie He, Hongyan Fan · 2025 · Diabetology & Metabolic Syndrome
20. Role of epicardial adipose tissue in heart failure with preserved ejection fraction: An emerging molecular mechanism and therapeutic potential
    Zhongwen Qi, Dan Wu, Zhipeng Yan, Qing Wang, Yiming Li, Junnan Zhao, Fengqin Xu · 2025 · Obesity Reviews
21. Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes
    HARPREET SINGH BAJAJ, Badr A. Aljabri, Subodh Verma · 2018 · Current Opinion in Cardiology
22. Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease
    Turgay Saritas, Sebastian Daniel Reinartz, Jennifer Nadal, Jonas Schmoee, Matthias C. Schmid, Mohamed Marwan, Stephan S. Achenbach, Stefan Störk, Christoph Wanner, Kai‐Uwe Eckardt et al. · 2019 · Clinical Kidney Journal
23. Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease
    Mohammed Eslam, Jacob George · 2019 · Hepatology International
24. Epicardial Adipose Tissue: A Precise Biomarker for Cardiovascular Risk, Metabolic Diseases, and Target for Therapeutic Interventions
    Aleksander M. Bogdanski, Piotr Niziołek, Stanisław Kopeć, Małgorzata Moszak · 2024 · Cardiology in Review
25. Pericardium, epicardial adipose tissue, and heart failure with preserved ejection fraction: Pathophysiology, quantification and treatment target
    Ana Teresa Timóteo, Francisco Barbas de Albuquerque, Bárbara Lacerda Teixeira · 2024 · International Journal of Cardiology
26. Obesity as a risk factor in atrial fibrillation and heart failure
    Jakub Jurica, Martin Jozef Péč, Jakub Benko, Tomáš Bolek, Péter Galajda, Marian Mokáň, Matej Samoš · 2023 · Journal of Diabetes & Metabolic Disorders
27. Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction
    Tianyu Wang, Qiang Yang, Xin-Yi Cheng, Jun-Can Ding, Peng-Fei Hu · 2024 · Heart Failure Reviews
28. Epicardial Fat in Heart Failure and Preserved Ejection Fraction: Novel Insights and Future Perspectives
    Jacob Whitman, Elie Kozaily, Erin D. Michos, Daniel N. Silverman, Marat Fudim, Robert John Mentz, Ryan James Tedford, Vishal N. Rao · 2025 · Current Heart Failure Reports
29. Association Between Left Atrial Epicardial Adipose Tissue Attenuation Assessed by Cardiac Computed Tomography and Atrial Fibrillation Recurrence Following Catheter Ablation: A Systematic Review and Meta-Analysis
    Karol Momot, Kamil Krauz, Michał Pruc, Łukasz Szarpak, Dariusz Rodkiewicz, Artur Mamcarz · 2025 · Journal of Clinical Medicine
30. The Liraglutide Effects in Atrial Fibrillation (LEAF) Study
    Jeffrey J. Goldberger, Raul David Mitrani, Joel E. Fishman, Ghaith Zaatari, Maureen H. Lowery, Carmen Baez-Garcia, Valeria Aguilar, Catherine Blandon, Barry E. Hurwitz, Alex H. Velasquez et al. · 2026 · JACC. Clinical electrophysiology
31. Epicardial Adipose Tissue and Development of Atrial Fibrillation (AFIB) and Heart Failure With Preserved Ejection Fraction (HFpEF)
    Sarmad Zain, Talha Shamshad, Ahmad Kabir, Ahmad Ali Khan · 2023 · Cureus
32. Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action
    Bykova Aa, Maria Serova, M. I. Chashkina, Raisa S. Kosharnaia, Z. K. Salpagarova, Denis A. Andreev, Ilya Giverts · 2024 · Cardiac failure review
33. Uncovering the role of prokineticin pathway on Epicardial Adipose Tissue (EAT) development and EAT-associated cardiomyopathy
    Martina Vincenzi, Canan G. Nebigil · 2025 · Trends in Cardiovascular Medicine
34. Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
    Turkistani, Yosra · 2025 · Frontiers in Cardiovascular Medicine
35. Effects of glucagon‐like peptide‐1 receptor agonists on major coronary events in patients with type 2 diabetes
    Xueyuan Guo, Caihua Sang, Ribo Tang, Chenxi Jiang, Songnan Li, Nian Liu, Deyong Long, Xin Du, Jianzeng Dong, Changsheng Ma · 2023 · Diabetes Obesity and Metabolism
36. Influence of modern antidiabetic therapy on body weight in patients with type 2 diabetes mellitus
    В. В. Салухов, Т. A. Ilyinskaya, Alexey A. Minakov · 2022 · Endocrinology News Opinions Training
37. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients
    Sten Madsbad · 2019 · Expert Review of Cardiovascular Therapy
38. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Milton Packer · 2018 · The American Journal of Medicine
39. Strategies and methods for the correction of obesity and associated cardiovascular risk
    Т. Yu. Kuznetsova, М. A. Druzhilov, Galina A. Chumakova, Nadezhda G. Veselovskaya · 2019 · Russian Journal of Cardiology
40. Beyond the Calcium Score: What Additional Information from a CT Scan Can Assist in Cardiovascular Risk Assessment?
    Federico Bernardini, Martina Gelfusa, Mihail Celeski, Federica Coletti, Annunziata Nusca, Domenico De Stefano, Francesco Piccirillo, Fabio Mangiacapra, Paolo Gallo, Valeria Cammalleri et al. · 2022 · Applied Sciences
41. Epicardial adipose tissue as target of the incretin-based therapies in cardio-metabolic pathologies: a narrative review
    Andrea S.K. Pop, Maria D. Dănilă, Silvia Giuchici, Darius G. Buriman, Bogdan M. Lolescu, Adrian Sturza, Danina Mirela Muntean, Ana Lascu · 2025 · Canadian Journal of Physiology and Pharmacology
42. From Cushion to Culprit: The Role of Epicardial Adipose Tissue in Cardiovascular Disease
    Shaun Khanna, G. V. Mann, Sheran A. Vasanthakumar, Clare Gabrielle Arnott, Nitesh Nerlekar · 2025 · Heart Lung and Circulation
43. Heart matters: How glucose‐ and lipid‐modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning
    Elisabeth Heuboeck, Charnkamal Singh Bhogal, Markus Mandl · 2025 · Diabetes Obesity and Metabolism
44. Multifactorial mechanisms of obesity-related HFpEF: the central role of epicardial adipose tissue and therapeutic perspectives
    Yuxin Zhou, Han Yan, Yao Zhu, Weimin Jiang, Shujie Zhang · 2025 · Frontiers in Cardiovascular Medicine
45. Effect of dapagliflozin on epicardial fat volume in patients with acute coronary syndrome assessed by computed tomography
    Hilda Elizabeth Macías-Cervantes, Diana Berenice Martínez-Ramírez, Luis Ricardo Hinojosa-Gutiérrez, Daniel Armando Córdova-Silva, Jair Antonio Rios-Muñoz · 2023 · Current Problems in Cardiology
46. Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy
    Gianluca Iacobellis, Sara Basilico, Alexis Elias Malavazos · 2022 · Handbook of experimental pharmacology
47. MR Assessed Changes of Renal Sinus Fat in Response to Glucose Regulation in West European and South Asian Patients With Type 2 Diabetes
    Ling Lin, Ilona A. Dekkers, Qian Tao, Elisabeth H.M. Paiman, Maurice B. Bizino, Ingrid M. Jazet, Hildo J. Lamb · 2023 · Journal of Magnetic Resonance Imaging
48. Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
    Tirandi, Amedeo, Montecucco, Fabrizio, Carbone, Federico, Liberale, Luca · 2024 · Polish Archives of Internal Medicine
49. Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
    Ying Jie Chee, Rinkoo Dalan · 2024 · Biomedicines
50. Cardioprotective Heme Oxygenase 1‐PGC1α Signaling in Epicardial Fat Attenuates Cardiovascular Risk in Humans as in Obese Mice
    Stephen J. Peterson, Rahul Yadav, Gianluca Iacobellis · 2019 · Obesity
51. Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models
    Jenpei Lee, Yingxiao Li, Juei‐Tang Cheng, I-Min Liu, Kai‐Chun Cheng · 2024 · Pharmaceuticals
52. Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial
    Konstantin Alexander Krychtiuk, Guillaume Marquis‐Gravel, Shannon Murphy, Karen Chiswell, Jennifer B. Green, Lawrence A. Leiter, Renato D. Lópes, Stefano Del Prato, John J.V. McMurray, Adrian F. Hernandez et al. · 2024 · European Journal of Preventive Cardiology
53. Roles of perivascular adipose tissue in the pathogenesis of atherosclerosis ― an update on recent findings
    Tomoya Hara, Masataka Sata · 2025 · Frontiers in Physiology
54. Cardiac magnetic resonance quantified epicardial fat volume is associated with complex coronary artery disease among diabetics
    Shimaa Sayed Khidr, Bakeer Mohamed Bakeer, Hatem Abdel Rahman Helmy, Heba Mahmoud El-Naggar · 2025 · Cardiovascular Diabetology
55. The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
    Xiangling Duan, Xiaomeng Zhang, Bao Sun · 2025 · Cardiovascular Diabetology
56. Advances and challenges of targeting epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT)
    Dan Liu, Wujun Chen, Zhu Guo, Qun Gao, Bin Wang, Jie Wang, Weichao Hu, Chao Wang, Shuai Wang, Xiaolin Wu et al. · 2025 · Cardiovascular Diabetology
57. Mechanisms of Glucagon‐Like Peptide 1 Receptor Agonist‐Induced Facial Lipodystrophy and a Path Toward Prevention
    Ilja L. Kruglikov · 2025 · Journal of Cosmetic Dermatology
58. Epicardial Adipose Tissue as an Independent Risk Factor for Mortality in Pulmonary Arterial Hypertension
    Breanne E. McCarthy, Rui Feng, Drew A. Torigian, Yubing Tong, Jason S. Fritz, Jasleen Minhas, Jeremy Aryeh Mazurek, Kerri Akaya Smith, Harold I. Palevsky, Steven C. Pugliese et al. · 2024 · CHEST Journal
59. Modifiable Risk Factors and Atrial Fibrillation: the Quest for a Personalized Approach
    Lavinia-Lucia Matei, Cǎlin Silişte, Dragoş Vinereanu · 2021 · MAEDICA – a Journal of Clinical Medicine
60. Molecular Pathways in Diabetic Cardiomyopathy and the Role of Anti-hyperglycemic Drugs Beyond Their Glucose Lowering Effect
    Jie-Eun Lee, Byung Gyu Kim, Jong Chul Won · 2025 · Journal of Lipid and Atherosclerosis
61. Proarrhythmic Lipid Inflammatory Mediators: Mechanisms in Obesity Arrhythmias
    Pegah Bahrami Taqanaki, Kelly A. Aromolaran, Ademuyiwa S. Aromolaran · 2025 · Journal of Cellular Physiology
62. Clinical Role of Epicardial Adipose Tissue
    Paolo Raggi, Arthur E. Stillman · 2025 · Canadian Journal of Cardiology
63. Benefits of GLP-1 Mimetics on Epicardial Adiposity
    Habib Yaribeygi, Mina Maleki, Fatemeh Sokouti Nasimi, Tannaz Jamialahmadi, Fatima Cody Stanford, Amirhossein Sahebkar · 2023 · Current Medicinal Chemistry
64. Epicardial fat thickness in type 2 diabetes outpatient care
    Gianluca Iacobellis, Jeffrey J. Goldberger, Alexis Elias Malavazos, Carlos Munoz Sterling, Ayse Canturk · 2023 · Nutrition Metabolism and Cardiovascular Diseases
65. Cardiac CT scanning in coronary artery disease: Epicardial fat volume and its correlation with coronary artery lesions and left ventricular function
    Ruohan Yin, Xiaoqiang Tang, Tao Wang, Haifeng Shi, Xiang Wang, Xiaoqin Wang, Changjie Pan · 2020 · Experimental and Therapeutic Medicine
66. Research Progress on the Association Between GLP-1 Receptor Agonists and Cardiomyopathy
    Xiao Yang, Xinghui Li · 2025 · Reviews in Cardiovascular Medicine
67. Epicardial Fat Inflammation and GLP-1/GIP Receptor Analogs: Are we Shifting our Perspective?
    Gianluca Iacobellis · 2025 · Current Cardiology Reports
68. Epicardial adipose tissue and residual cardiovascular risk: a comprehensive case analysis and therapeutic insights with Liraglutide
    Fulvio Cacciapuoti, Ciro Mauro, Davide D’Andrea, Valentina Capone, Carlo Liguori, Federico Cacciapuoti · 2024 · Journal of Cardiovascular Medicine
69. Cardiometabolic Crossroads: Obesity, Sleep-Disordered Breathing, and Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction – A Mini-Review
    Fulvio Cacciapuoti, Ciro Mauro, Valentina Capone, Angelo Sasso, Luca Gaetano Tarquinio, Federico Cacciapuoti · 2024 · Heart and Mind
70. Epicardial adipose tissue, cardiac damage, and mortality in patients undergoing TAVR for aortic stenosis
    Pamela Piña, Daniel Lorenzatti, Annalisa Filtz, Andrea Scotti, Elena Virosta Gil, Juan Duarte Torres, Cristina Morante Perea, Leslee J. Shaw, Carl J. Lavie, Daniel S. Berman et al. · 2025 · The International Journal of Cardiovascular Imaging
71. Open-bore MRI Scanner Assessment of Epicardial Adipose Tissue after Bariatric Surgery: A Pilot Study
    Carmela Asteria, Francesco Secchi, Lelio F. Morricone, Alexis Elias Malavazos, Simona Francesconi, Valentina Milani, Alessandro Giovanelli · 2024 · Endocrine Metabolic & Immune Disorders - Drug Targets
72. Epicardial adipose tissue: a new link between type 2 diabetes and heart failure—a comprehensive review
    Si-jia Zhang, Siwei Wang, Shiyu Liu, Ping Li, De-lian Huang, Xi-xi Zeng, Tian Lan, Yeping Ruan, Hai-jiao Shi, Xin Zhang · 2024 · Heart Failure Reviews
73. Current updates on pharmacological roles of glucagon-like peptide 1 in obesity
    Rohit Kumar Verma, Raghava N. Sriramaneni, Manisha Pandey, Hira Chaudhury, Bapi Gorain, Gaurav Gupta · 2018 · Panminerva Medica
74. Targeting the organ-specific adiposity
    Gianluca Iacobellis, Giuseppe Bárbaro · 2018 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
75. Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
    Khushali Trivedi, Vernon Wayne Dolinsky · 2026 · Canadian Journal of Physiology and Pharmacology
76. Relationship Between Epicardial Fat Volume and Coronary Microvascular Dysfunction
    Tsuyoshi Ito, Atsushi Niwa, Masashi Yokoi, Shuichi Kitada, Yu Kawada, Tatsuya Mizoguchi, Shohei Kikuchi, Sayuri Yamabe, Toshihiko Goto, Yoshihiro Seo · 2025 · Circulation Reports
77. Ischemia with Nonobstructive Coronary Artery Disease and Atrial Cardiomyopathy—Two Sides of the Same Story?
    Irina Afrăsânie, Iulian Theodor Matei, Sabina Andreea Leancă, Adriana Chetran, Alexandru Dan Costache, Vlad-Adrian Afrăsânie, Bianca-Ana Dmour, Daniela Crișu, Minerva Codruța Bădescu, Lăcrămioara Șerban et al. · 2023 · Life
78. Obesity: Rubensian beauty turned into major health problem
    Sandor George Vari · 2017 · Croatian Medical Journal
79. Novel Strategies to Conquer Residual Adiposity Risk in Cardiovascular Disease
    Jerrin S. Philip, Aayush Shah, Eleonora Avenatti · 2025 · Current Atherosclerosis Reports
80. Predictive Value of Epicardial Adipose Tissue Parameters Measured by Cardiac Computed Tomography for Recurrence of Atrial Fibrillation After Pulmonary Vein Isolation
    Karol Momot, Michał Pruc, Dariusz Rodkiewicz, Edward Koźluk, Kamil Krauz, Agnieszka Piątkowska, Zuzanna Zalewska, Małgorzata Buksińska−Lisik, Łukasz Szarpak, Artur Mamcarz · 2025 · Journal of Clinical Medicine
81. Epicardial Adipose Tissue: A Potential Target to Improve Left Ventricular Diastolic Dysfunction
    Chun-Qiong Ran, Wen‐Tao He · 2025 · Reviews in Cardiovascular Medicine
82. Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure
    Simone Pasquale Crispino, Annunziata Nusca, Aurora Ferro, Riccardo Cricco, Martina Ciancio, Andrea Segreti, Ilaria Cavallari, Mario Sabatino, Luciano Potena, Gian Paolo Ussia et al. · 2025 · Biomolecules
83. Cardiac MRI in diabetic cardiomyopathy: translating imaging biomarkers into clinical practice
    Shan Huang, Xueming Li, Lu Zhang, Ran Sun, Hanrui Liu, Xinyuan Zhang, Ke Shi, Li Jiang, Hildo J. Lamb, Zhigang Yang et al. · 2025 · Cardiovascular Diabetology
84. GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
    Prerana Ramadurgum, Kunal M. Sharma, Alec Pinon, Lakshmi Prasanna Vaishnavi Kattamuri, Monica Botros · 2026 · Current Cardiology Reports
85. The Management of Obesity Before Catheter Ablation of AF: The Missing Piece?
    Kyaw Zaw Win, Matthew James Armstrong, Richard Paul Steeds, Manish Kalla · 2025 · Arrhythmia & Electrophysiology Review
86. Impact of epicardial adipose tissue volume on hemodynamically significant coronary artery disease in Chinese patients with known or suspected coronary artery disease
    Xiangbo Jin, Beibei Gao, Jiamin Zheng, Xueer Wu, Ning Zhang, Lijun Zhu, Xinyu Zhu, Jianchang Xie, Zhen Wang, Guoxin Tong et al. · 2023 · Frontiers in Cardiovascular Medicine
87. ROLE OF LIRAGLUTIDE IN THE TREATMENT OF OBESITY IN CHILDREN
    Н.В. Евдокимова · 2023 · University therapeutic journal
88. Tissu adipeux épicardique et fibrillation auriculaire
    Lea Iten, Patrice Carroz, Giulia Domenichini, Denis Graf, Claudia Herrera, Mathieu Le Bloa, Pierre A Monney, Alessandra Pia Porretta, Patrizio Pascale, Etienne J. Pruvot et al. · 2022 · JMIG
89. Epicardial adipose tissue (dys)function: A new player in heart disease?
    Paulo N. Matafome · 2020 · Revista Portuguesa de Cardiologia
90. Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease
    Bo Kyung Koo, Soo Kyung Lim · 2022 · Wiley eBooks
91. Visceral adiposity: A major mediator of the relationship between epicardial adiposity and cardiorespiratory fitness in adults
    Dominic J. Chartrand, Éric Larose, Paul Poirier, Patrick Mathieu, Natalie Alméras, Philippe Pîbarot, Benoı̂t Lamarche, Caroline Rhéaume, Isabelle Lemieux, Jean‐Pierre Després et al. · 2024 · Nutrition Metabolism and Cardiovascular Diseases
92. Epicardial adipose tissue in coronary microvascular disease
    Veronika Gašpárková, Bao Thai Tran, Petr Ošťádal, Lukáš Lambert, Petr Hájek, Petr Kala · 2026 · American Heart Journal Plus Cardiology Research and Practice
93. Epicardial adipose tissue as a determinant of heart failure prognosis: insights across ejection fraction phenotypes
    Marcel Nowakowski, Maciej Mazuruk, Łukasz Nogajski, Maciej Mączewski, Hanna Czerwińska, Mikołaj Kurpias, Michał Mączewski, Aleksandra Paterek · 2026 · Cardiovascular Diabetology
94. GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease
    Parth M. Dhamelia, Ninad Khandekar, Srikanth Vallurupalli, Jorge Saucedo, John M. Arthur, Dharmik Jadvani, Vikram R. Beemidi, Nishank Jain · 2026 · Cardiovascular Drugs and Therapy
95. Atrial Fibrillation and Epicardial Adipose Tissue
    Ghaith Zaatari, Jeffrey J. Goldberger · 2020 · Contemporary cardiology
96. Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery
    Leyla Seymurovna Namazova-Baranova, Eduard T. Ambarchyan, Vladislav V. Ivanchikov, Anastasia D. Kuzminova, A. G. Shandra, Еlena A. Vishneva, Grigory V. Revunenkov, Kirill A. Valyalov · 2023 · Вопросы современной педиатрии
97. Pharmacological and Non-Pharmacological Interventions in Diabetes Mellitus: Effects on Epicardial Adipose Tissue
    Krzysztof Kuleta, Kamil Krauz, Jakub Żmuda, Karol Momot, Maciej Zarębiński, Izabela Poprawa, Małgorzata Wojciechowska · 2025 · International Journal of Molecular Sciences
98. Epicardial fat: a new cardiometabolic risk marker, a new therapeutic goal in obese patients
    Nataliya V. Blinova, Yu. V. Zhernakova, M O Azimova, Азимова Макка Ризвановна, Irina Evgen'evna Chazova · 2018 · Systemic Hypertension
99. Herzinsuffizienz mit erhaltener Ejektionsfraktion als Modellerkrankung für das kardio-pulmo-renale Syndrom
    Carsten Tschöpe, Ahmed Elsanhoury, Vivian Nelki, Sophie Van Linthout, Sebastian Kelle, Andrew B Remppis · 2021 · Der Internist
100. Epicardial adipose tissue (dys)function: A new player in heart disease?
     Paulo N. Matafome · 2020 · Revista Portuguesa de Cardiologia (English Edition)